还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

" u: o, s7 s( U7 [4 h                               
登录/注册后可看大图

. h- K, P% j, {2 I" b0 }* h6 ?7 H  o请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

+ g0 V9 F( k$ F5 a; B2 ~8 M可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  


Sub-category:
Molecular Targets
- ?! n, }: @' k; a- l
6 y) W0 P. L' N+ N
Category:
Tumor Biology

& `! v% Q6 o2 c6 {
Meeting:
2011 ASCO Annual Meeting

: L# P& W8 h1 n/ e% ?
Session Type and Session Title:
Poster Discussion Session, Tumor Biology
+ S* P4 U+ T' X% j5 V7 z" t5 F

Abstract No:
* a9 ?- d9 D, Q' ]- G10517

% _, T  g$ h9 X# x; e5 Y0 n& |# }8 ?
! _7 S3 _! a& {) B1 s1 ZCitation:
J Clin Oncol 29: 2011 (suppl; abstr 10517)
3 }" n7 o# r) L& e% v' L: o

Author(s):
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China


3 E. M! {5 r$ k# H: p
3 A: c# r- x* p& c+ p, p: |* U0 kAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

Abstract Disclosures
+ g9 u: @7 O5 b) }
) p; [# O4 a: v" YAbstract:

, e* \3 h# V& V# c; h5 }7 j
4 f7 I  [; U7 Y9 A1 l. HBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
+ F' {% F! i3 f* v- s# [7 Z& y
4 J: o) @) h/ _& F3 X7 j

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

4 I; c0 a4 [( V- w: K. F4 v没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

' Y/ m4 ~3 R1 |; {; }( ~易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
6 E5 d! [/ `  `) bALK一个指标医院要900多 ...

) L, K2 x9 t* a% u平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？
2 u9 F( t- D' ]; }2 g4 }
现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊